Com-COV vaccine mix-and-match study expands to 12-to-16-year-olds

September 18, 2021

This will provide the JCVI with information crucial to informing their advice about immunising teenagers in the UK.’Participants can either receive two COVID-19 vaccine doses in the study, in which case their first dose will be the Pfizer COVID-19 vaccine.Alternatively, those who have already received a dose of the Pfizer COVID-19 vaccine through the NHS can be enrolled at the time of their second dose.All participants will be randomly allocated at the time of the second dose to receive either a full dose or half dose of the Pfizer-BioNTech vaccine, a full dose of the Novavax vaccine or a half dose of the Moderna vaccine.In May, researchers reported preliminary Com-COV data revealing more frequent mild to moderate reactions in mixed schedules compared to standard schedules, however, these were short-lived in duration.In April, the researchers expanded the programme to include the Moderna and Novavax vaccines in a new study.

The source of this news is from University of Oxford